The US Department of Health and Human Services is requesting significant revisions to testosterone replacement therapy labels after reviewing new data that challenges longstanding government restrictions on the treatment, a move that could expand access for millions of American men while raising questions about appropriate medical oversight.
The requested label changes would include removing a statement that the safety and effectiveness of testosterone replacement therapy have not been established in men with age-related low testosterone, HHS announced Thursday. The agency also calls for updating information related to prostate cancer risk and revising warnings regarding enlarged prostate.
Reversing Decade-Old Restrictions
The announcement represents a notable shift from the eleventh year of FDA-mandated restrictions. In 2015, the US Food and Drug Administration required label changes on testosterone therapy that stated the safety and effectiveness had not been established for men who had signs and symptoms associated with idiopathic hypogonadism, a condition that involves low testosterone levels. That limitation was added because, according to HHS, "evidence of benefit was limited and concerns had been raised about possible cardiovascular risks."
HHS Secretary Robert F. Kennedy Jr. said in the announcement, "By updating testosterone therapy labels to reflect current evidence, we are giving patients and physicians clearer information, supporting informed medical decisions, and improving care for millions of American men."
HHS said additional research has since emerged, including a large clinical study involving more than 5,200 men that found no "meaningful increase" in major cardiovascular events, such as heart attack or stroke, among people receiving testosterone therapy.
Prostate Cancer and Enlarged Prostate Guidance
HHS also said current labels generally advise against testosterone therapy in men who have known or suspected prostate cancer and caution that treatment may increase the risk of developing the disease, but more recent research data "have not generally shown an increased risk of prostate cancer in men receiving testosterone replacement therapy." Under the requested revisions, the therapy would be advised against only in men whose prostate cancer has spread.
For enlarged prostate, HHS said current labels generally warn that testosterone therapy may worsen symptoms of benign enlarged prostate, but a new FDA review found no evidence of that happening in men with mild to moderate versions of the condition. For men with more severe symptoms, HHS said evidence remains limited and "the labeling changes requested would recommend continued monitoring of patients with severe symptomatic disease during treatment."
Dr. Adam Baumgarten, associate professor in the University of Alabama at Birmingham Department of Urology, said the new HHS request to change the warning labels on testosterone therapy have been "a long time coming." Baumgarten said, "The first major takeaway is that the cardiovascular safety concerns that have surrounded testosterone therapy for the past decade are no longer supported by randomized trial data." He said, "Second, the FDA has meaningfully narrowed its prostate cancer warning. Rather than a broad caution against use in men with a history of prostate cancer, the focus is now more specifically on metastatic disease."
Medical Professionals Urge Caution
Dr. Jamin Brahmbhatt, a urologist and men's health expert at Orlando Health in Florida, said the government has only requested updates to testosterone therapy product labels, and no changes have been officially made yet. Brahmbhatt said, "And taking a warning off a label isn't the same as saying every man should be on it." He also said, "Testosterone is still a medical therapy, not a wellness drug. This new proposal should not make it the wild wild west for prescribers and patients – there still need to be guardrails in place, like for any medical therapy. I'm also hopeful clearer labels help more insurers cover it for the men who truly need it."
Baumgarten added, "Third, this is not a signal for indiscriminate use. Testosterone therapy still requires a clear diagnosis based on both symptoms and consistently low testosterone levels, and men on therapy require ongoing monitoring with appropriate laboratory follow-up."
Healthcare providers generally consider testosterone levels below 300 nanograms per deciliter of blood as low in adults. Brahmbhatt said normal testosterone levels in men can range widely, from around 300 to more than 800 nanograms per deciliter, depending on which guidelines are followed or which lab tests were conducted.
Brahmbhatt said that when prescribing testosterone, he looks for "a level that's genuinely low, confirmed on two separate morning blood draws when testosterone naturally peaks," and he makes sure it aligns with symptoms, such as low sex drive, fatigue, trouble with erections or loss of muscle. Brahmbhatt said, "For a man who is genuinely low, the benefits are real: improved energy, sex drive, mood, muscle, and bone strength." He also said, "For a man whose levels are already in a normal range and who's just chasing an improvement in health motivated by online influencers, the risks may not outweigh the benefits."
Dr. Eddie Hackler III, an Atlanta-based cardiologist and author of the book Follow Your Heart, said the new HHS request to change the language on labels "removes the fear" around testosterone replacement therapy. Hackler said, "Testosterone therapy has proven benefits for specific symptoms; particularly improved libido, sexual function, correction of anemia, and modest improvements in mood and energy. Proper diagnosis is essential before starting therapy." He also said, "Testosterone therapy does not appear to increase the risk of heart attacks, strokes, or prostate cancer based on the best available randomized trial data."
Hackler added that potential risks and side effects may include skin reactions, acne, enlargement of male breast tissue, pulmonary embolism or blood clots, irregular heart rhythms, suppression of sperm production and minimal increase in blood pressure.
Brahmbhatt added, "I don't want anyone overpromising here. Testosterone can suppress a man's own sperm production, it can thicken the blood, and the long-term prostate picture still isn't fully clear."
Administration Hormone Therapy Initiative
The new move by HHS is the latest in the Trump administration's efforts to reduce restrictions on hormone therapies. Last year, the administration took similar steps on hormone therapy for women when the FDA removed black box warnings from menopausal hormone therapy products. In December, the FDA hosted an expert panel discussion on testosterone replacement therapy for men. Since then, the agency has been looking into potential new treatment options involving testosterone therapy for men.
Why This Matters:
The requested label revisions represent a significant reduction in federal regulatory barriers that have constrained physician discretion and patient access for over a decade. By aligning government warnings with current clinical evidence rather than precautionary assumptions, the changes could reduce insurance denials and expand treatment options for men with documented medical need. The move reflects a broader regulatory philosophy that prioritizes individual medical decision-making between patients and physicians over blanket government restrictions. However, the emphasis from medical professionals on proper diagnosis and monitoring underscores that removing regulatory obstacles does not eliminate the need for responsible medical practice. The potential for expanded insurance coverage mentioned by practitioners suggests the label changes could have meaningful fiscal implications for both patients and healthcare systems, while the administration's pattern of reducing hormone therapy restrictions across multiple categories indicates a consistent approach to medical regulation that favors evidence-based access over precautionary limitations.",
"media